Audit of cyclosporin use in inflammatory bowel disease: Limited benefits, numerous side-effects

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 6, 2000, Pages 657-660

  Haslam, Neil ^a   Hearing, Stephen D ^b   Probert, Christopher S J ^b  

^a GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Crohn's disease; Cyclosporin; Side effects; Ulcerative colitis

Indexed keywords

CYCLOSPORIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLITIS; CROHN DISEASE; DISEASE DURATION; ENTERITIS; HUMAN; IMMUNOMODULATION; MEDICAL AUDIT; PRIORITY JOURNAL; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED KINGDOM;

EID: 0033945970     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012060-00015     Document Type: Article

References (15)

1. 1 Carpani de Kaski M, Hodgson HJF. Inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7:567-579.
2. 2 Podolsky DK. Inflammatory bowel disease. Parts 1 and 2. N Engl J Med 1991; 325:928-937 and 1008-1116.
3. 3 Targan SR, Shanahan F. Inflammatory bowel disease, from bench to bedside. Hagerstown, MD: Williams & Wilkins; 1994.
4. 4 Truelove SC, Willoughby CP, Lee EG, Kettleworth MGW. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; ii:1086-1088.
5. 5 Ho S, Clipstone N, Timmerman L, Northrop J, Graef I, Fiorentino D. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80:S40-S45.
6. 6 Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
7. 7 Hyde GM, Jewell DP. The management of severe ulcerative colitis. Aliment Pharmacol Ther 1997; 11:419-424.
8. 8 Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflam Bowel Dis 1995; 1:48-63.
9. 9 Brynskov J, Freund L, Rasmussen SN, Lauritsen K, De Muckadell OS, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporin in active Crohn's disease. N Engl J Med 1989; 321:1845-1850.
10. 10 Feagan BG, McDonald JWD, Rochaon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846-1851.
11. 11 Stange EF, Modigliani R, Pena AS, Wood AJ, Feurten G, Smith PR. European trial of cyclosporine in active Crohn's disease: a 12 month study. Gastroenterology 1995; 109:774-782.
12. 12 Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory and fistulating Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93:442-448.
13. 13 Hinterleitner TA, Petritsch W, Aichbichler B, Fickert P, Ranner G, Krejs GJ. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Z Gastroenterol 1997; 35:603-608.
14. 14 Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10:411-413.
15. 15 Stein R, Cohen R, Hanauer S. Complications during cyclosporine therapy for inflammatory bowel disease. Gastroenterology 1997; 112:A1096.